YourChoice Therapeutics Celebrates Second Publication in Nature
YourChoice Therapeutics Advances Male Contraception with Second Nature Portfolio Publication Showcasing Human Trial Data for YCT-529 YourChoice Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the development of hormone-free contraceptive solutions,…
Charles River Collaborates with Elly to Advance Gene Therapies for Rare Diseases
Charles River Teams Up with Elly’s Team to Accelerate Gene Therapy for Ultra-Rare NEDAMSS Disorder Charles River Laboratories International, Inc. (NYSE: CRL), a global leader in early-stage drug development and…
Alloy Therapeutics and KSAC Partner to Boost Global Growth of Japanese Biotech Startups
Alloy Therapeutics and KSAC Forge Strategic Alliance to Propel Global Growth of Japanese Life Science Startups Alloy Therapeutics Co. Ltd. (“Alloy Japan”) has entered into a strategic Memorandum of Understanding…
Takeda Secures FDA 510(k) Clearance for HyHub™ and HyHub™ Duo to Streamline HYQVIA® Delivery
Takeda Gains FDA 510(k) Clearance for HyHub™ and HyHub™ Duo to Enhance HYQVIA® Administration Experience for Patients with Primary Immunodeficiency and CIDP Takeda (TSE:4502/NYSE:TAK), a global biopharmaceutical leader, announced that…
WHO Operations Disrupted After Attacks on Gaza Warehouse and Staff Shelter
WHO Strongly Condemns Attacks on Staff Shelter and Warehouse in Gaza as Humanitarian Health Operations Reach Breaking Point The World Health Organization (WHO) has issued a forceful condemnation of recent…
WuXi Biologics Gets FDA Nod for Five Sites, Including First Commercial PFS Line
WuXi Biologics Achieves Major Regulatory Milestone with FDA Pre-License Inspection Clearance for Five Facilities, Including First Commercial Pre-Filled Syringe Site WuXi Biologics (HKEX: 2269), a global leader in Contract Research,…
Bristol Myers’ sNDA for Sotyktu in Psoriatic Arthritis Accepted in Four Global Regions
Bristol Myers Squibb’s Sotyktu Makes Global Regulatory Progress for Psoriatic Arthritis as FDA Accepts sNDA for Review In a major development for immunology-focused therapeutics, Bristol Myers Squibb (NYSE: BMY) has…
Sarepta Therapeutics Issues Update on ELEVIDYS Program
Sarepta Therapeutics Responds to FDA’s Voluntary Halt Request for ELEVIDYS Shipments and Clarifies Gene Therapy Safety Concerns Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a leading biotechnology company at the forefront of…
Genentech Updates sBLA for Columvi Combo in R/R DLBCL
Genentech Receives FDA Complete Response Letter for Columvi Combination Therapy in Second-Line Diffuse Large B-Cell Lymphoma; Reaffirms Commitment to Advancing Columvi Across the Treatment Landscape Genentech, a member of the…
Wedgewood Enhances Veterinary Expertise with Two New Advisory Councils
Wedgewood Expands and Evolves Its Veterinary Advisory Committee with the Launch of Two New Councils to Strengthen Clinical Collaboration and Strategic Insight Wedgewood, a long-standing leader in veterinary pharmacy and…
MEI Pharma raises $100M, adopts Litecoin treasury plan, and adds Charlie Lee to board
MEI Pharma Makes Historic Move with $100 Million Private Placement to Launch Litecoin-Based Treasury Strategy, Appoints Charlie Lee to Board In a bold and unprecedented move that bridges the worlds…
Bristol Myers Squibb Reports Phase 3 Results for Reblozyl in Myelofibrosis Anemia
Bristol Myers Squibb Reports Topline Results from Phase 3 INDEPENDENCE Trial of Reblozyl in Myelofibrosis-Associated Anemia Bristol Myers Squibb (NYSE: BMY), a global leader in hematology and oncology innovation, has…